Zogenix (ZGNX) Rating Lowered to Hold at BidaskClub

Zogenix (NASDAQ:ZGNX) was downgraded by equities researchers at BidaskClub from a “buy” rating to a “hold” rating in a report released on Friday, BidAskClub reports.

A number of other research firms have also commented on ZGNX. Zacks Investment Research raised shares of Zogenix from a “sell” rating to a “hold” rating in a research report on Saturday, February 2nd. Mizuho reaffirmed a “buy” rating and set a $69.00 price objective on shares of Zogenix in a report on Wednesday, February 6th. Finally, Northland Securities set a $70.00 price objective on shares of Zogenix and gave the stock a “buy” rating in a report on Tuesday, March 19th. Two equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. Zogenix has a consensus rating of “Buy” and a consensus target price of $70.00.

ZGNX opened at $52.00 on Friday. The company has a market capitalization of $2.18 billion, a P/E ratio of -16.10 and a beta of 2.17. Zogenix has a twelve month low of $33.43 and a twelve month high of $62.75.

In other Zogenix news, Director Roger Hawley sold 20,700 shares of Zogenix stock in a transaction that occurred on Friday, March 29th. The stock was sold at an average price of $55.00, for a total value of $1,138,500.00. Following the transaction, the director now directly owns 15,575 shares of the company’s stock, valued at approximately $856,625. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Renee P. Tannenbaum sold 17,503 shares of the company’s stock in a transaction that occurred on Wednesday, March 6th. The stock was sold at an average price of $50.65, for a total value of $886,526.95. Following the transaction, the director now owns 19,375 shares of the company’s stock, valued at $981,343.75. The disclosure for this sale can be found here. Insiders sold a total of 221,796 shares of company stock worth $10,893,436 in the last ninety days. Insiders own 4.60% of the company’s stock.

Institutional investors have recently made changes to their positions in the company. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Zogenix by 20.2% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,956 shares of the company’s stock valued at $108,000 after purchasing an additional 496 shares during the last quarter. SG Americas Securities LLC bought a new position in shares of Zogenix during the 3rd quarter worth about $109,000. Great West Life Assurance Co. Can increased its holdings in shares of Zogenix by 44.9% during the 4th quarter. Great West Life Assurance Co. Can now owns 5,382 shares of the company’s stock worth $189,000 after purchasing an additional 1,668 shares during the period. Prudential Financial Inc. acquired a new position in shares of Zogenix during the third quarter valued at about $219,000. Finally, Amalgamated Bank acquired a new position in shares of Zogenix during the fourth quarter valued at about $219,000.

About Zogenix

Zogenix, Inc, a pharmaceutical company, develops and commercializes therapies for the treatment of transformative central nervous system disorders in the United States. Its lead product candidate is the Fintepla/ZX008, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome.

Featured Story: What is the Quick Ratio?

Analyst Recommendations for Zogenix (NASDAQ:ZGNX)

Receive News & Ratings for Zogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zogenix and related companies with MarketBeat.com's FREE daily email newsletter.